Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

News Industry News

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

November 23, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

News Industry News

Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

September 29, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Industry News

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

July 24, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Industry News

Celladon says may liquidate; suspends gene therapy development

June 29, 2015

News Industry News

A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

May 28, 2015

News Industry News

Antiplatelet Drug Ticagrelor More Effective Than Clopidogrel for Ad Hoc PCI Patients

May 07, 2015

News Industry News

Sanofi and MyoKardia Announce Groundbreaking Collaboration to Develop Targeted Therapies for Patients with Genetic Heart Disease

September 17, 2014

News Industry News

Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab

August 25, 2014

News Industry News

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

July 30, 2014

News Industry News

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session

March 27, 2014

News Industry News

New Study Finds Patients who are Event-Free Following PCI at One Year May Not Need Prolonged Dual Antiplatelet Therapy

October 31, 2013

News Industry News

Study Find Pre-Hospital Administration of Bivalirudin Substantially Improves Outcomes Compared to Heparin in Heart Attack Patients

October 30, 2013

News Industry News

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

October 24, 2012

News Industry News

Low CV Event Rate Prompts Closure of Prasugrel Trial

November 09, 2011

News Industry News

Non-adherence to dual antiplatelet therapy following percutaneous coronary intervention results in higher rates of ischemic and bleeding events

November 08, 2011

News Industry News

Clinical trial comparing Prasurgrel to Clopidogrel following percutaneous coronary intervention is ended early

November 08, 2011

News Industry News

Cangrelor provides effective maintenance of platelet inhibition without major bleeding for patients who require bypass surgery

November 08, 2011

Advertisement

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

Celladon says may liquidate; suspends gene therapy development

A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

Antiplatelet Drug Ticagrelor More Effective Than Clopidogrel for Ad Hoc PCI Patients

Sanofi and MyoKardia Announce Groundbreaking Collaboration to Develop Targeted Therapies for Patients with Genetic Heart Disease

Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session

New Study Finds Patients who are Event-Free Following PCI at One Year May Not Need Prolonged Dual Antiplatelet Therapy

Study Find Pre-Hospital Administration of Bivalirudin Substantially Improves Outcomes Compared to Heparin in Heart Attack Patients

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

Low CV Event Rate Prompts Closure of Prasugrel Trial

Non-adherence to dual antiplatelet therapy following percutaneous coronary intervention results in higher rates of ischemic and bleeding events

Clinical trial comparing Prasurgrel to Clopidogrel following percutaneous coronary intervention is ended early

Cangrelor provides effective maintenance of platelet inhibition without major bleeding for patients who require bypass surgery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content